Ibandronic acid

IUPAC Name: [ 1-hydroxy-3-[ methyl ( pentyl ) amino ]-1-phosphonopropyl ] phosphonic acid
Synonyms of Ibandronic acid (CAS NO.114084-78-5): Ibandronic acid-D3 ;{ 1-Hydroxy-3-( methylpentylamino ) propylidene ]bisphosphnic Acid ; [1-Hydroxy-3-( methyl-d3-pentylamino ) propylidene ] bisphosphnic Acid ; Ibandronic ;1-Hydroxy-3-( methylpentylamino ) propylidene bisphosphonic acid ; Ibandronic acid ; P,P'-[ 1-Hydroxy-3-( methylpentylamino ) propylidene ] bisphosphonic Acid
Following is the molecular structure: 

CAS NO: 114084-78-5
Classification Code: Bone Density Conservation Agents
Molecular Formula: C₉H₂₃NO₇P₂
Molecular Weight: 319.2289
Melting Point: 113-115°C 
Polar Surface Area: 103.15 Å²
Index of Refraction: 1.537
Molar Refractivity: 68.85 cm³
Molar Volume: 220.2 cm³
Surface Tension: 70.8 dyne/cm
Density: 1.449 g/cm³
Flash Point: 309.3 °C
Enthalpy of Vaporization: 100.74 kJ/mol
Boiling Point: 587.8 °C at 760 mmHg
Vapour Pressure: 2.88E-16 mmHg at 25°C 

The uses of Ibandronic acid (CAS NO.114084-78-5): 
1.Ibandronic acid (INN) or ibandronate sodium (USAN), marketed under the trade names Boniva, Bondronat and Bonviva, is a potent bisphosphonate drug used in the prevention and treatment of osteoporosis.
2.It may also be used to treat hypercalcemia (elevated blood calcium levels). It is Marketed and Manufactured by GlaxoSmithKline and Roche Laboratories.

Indications of Ibandronic acid (CAS NO.114084-78-5): Ibandronate is indicated for the treatment and prevention of osteoporosis in post-menopausal women. Men should not take ibandronate unless they are participating in clinical trials. In May 2003, the U.S. Food and Drug Administration (FDA) approved Ibandronate as a daily, 2.50 mg dose treatment for post-menopausal osteoporosis. The basis for this approval was a three-year, randomized, double-blind, placebo-controlled trial of 2,946 women suffering post-menopausal osteoporosis. The participants received either a placebo or an oral ibandronate dose (2.50 mg), or intermittently (20 mg every second day in 12 doses at the beginning of each 3-month interval). Every participant also received daily oral doses of 500 mg of calcium and 400IUs [international units] of vitamin D. At the study's conclusion, both doses significantly reduced the occurrence risk of new vertebral fractures by 50–52 per cent when compared to the effects of the placebo drug.